A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors

Clinical trial NCT04592484 · COMPLETED

Trial details

NCT number: NCT04592484
Sponsor: Codiak BioSciences
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2020-09-15
Primary completion: 2022-08-03
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.